Friday, Apr 19 2024 | Time 10:25 Hrs(IST)
image
Business EconomyPosted at: Oct 4 2020 4:21PM


Tagoor Laboratories receives DCGI license to manufacture Favipiravir API

Hyderabad, Oct 4 (UNI) Tagoor Laboratories Private Limited has received Drugs Controller General of India (DCGI) license to manufacture Favipiravir API.

The Active Pharmaceutical Ingredients (API) of an Anti-Viral Drug was approved by the DCGI for use in the treatment of mild to moderate COVID-19 cases.
The manufacturing facility located in West Godavari district of Andhra Pradesh has successfully completed Favipiravir development and is planning to enhance its production capabilities, a company release here said on Sunday.
The DCGI earlier approved the use of Favipiravir, an anti-viral drug used for treatment of influenza.
The drug, developed in Japan, is also used for the treatment of mild to moderate cases of Covid-19 in India.
Favipiravir is a broad spectrum anti-viral agent and selectively inhibits RNA polymerase of influenza virus and prevents viral replication.
Commenting on the receiving the license, Dr P Kasi Viswanadha Raju, Managing Director said, “Tagoor Laboratories is capable of producing the drug without having to depend on any imports, as all the complex intermediates are developed in-house.
The Company is aiming to manufacture Favipiravir in quantities sufficient to meet the growing domestic demand, which arose due to the pandemic.
Additionally, Tagoor Laboratories also manufactures and supplies Hydroxychloroquine sulphate, also used to treat COVID-19 symptoms.
Our manufacturing facility, approved by the WHO GMP, clocked an annual turnover of Rs 270 crore in the financial year 2019-2020, and is expected to make a Revenue of Rs 450 crore in the fiscal 2020-2021.
The Company has its R&D facility in Jeedimetla Industrial area in Hyderabad.”
Business Head Dr Mohanbabu Maradolla said “Tagoor Laboratories Private Limited is in talks with the top buyers in the domestic market and is also making collaborations with various Turkish, Iran, Egypt, and Russia partners to supply the Favipiravir API.”
UNI VV CS 1619
Please log in to get detailed story.
Tags: #Tagoor Laboratories receives DCGI license to manufacture Favipiravir API
More News

Severe coal crisis: RINL to call for global tenders to procure 1 50L tons coal

18 Apr 2024 | 7:29 PM

Visakhapatnam (Andhra Pradesh), Apr 18 (UNI) In the backdrop of severe Coal crisis due to the ongoing strike at Adani Gangavaram Port Limited (AGPL),Rashtriya Ispat Nigam Limited (RINL) - Visakhapatnam Steel Plant (VSP), has embarked on a relentless mission to secure the crucial raw material of coal, which is essential for its safe and sustained operations.

see more..

Bajaj Auto net profit at Rs 1936 cr in Q4; clocks all-time high revenue in FY24

18 Apr 2024 | 6:46 PM

New Delhi, Apr 18 (UNI) Two wheeler auto major Bajaj Auto on Thursday announced 29 percent jump in its revenue in Q4 (January-March) at 11,485 crore, led by the broad based buoyancy that was sustained on the domestic business and aided by steady exports.

see more..

Entering share market can boost growth of SMEs: Infopark event

18 Apr 2024 | 6:31 PM

Kochi, Apr 18 (UNI) Small and marginal companies in Kerala enjoy immense scope for growth by entering the stock market, experts said at an Infopark-organised event here on Thursday.

see more..

18 Apr 2024 | 6:09 PM

New Delhi, Apr 18 (UNI) Angle One, a retail stock broking house in India, today announced 31 per cent jump in net profit at Rs 340 crore during Q4 of the last financial year over Rs 260.3 crore in the previous quarter.

see more..

Microsoft and ByteXL join hands to Present HackXcelerate 2024 at CBIT in Hyderabad

18 Apr 2024 | 5:57 PM

Hyderabad, Apr 18 (UNI) Microsoft, a global technology leader, has joined hands with ByteXL, a pioneering EdTech platform, to present HackXcelerate 2024, a nationwide hackathon aimed at igniting creativity and enhancing problem-solving skills among students.

see more..
image